Roider, Elisabeth
Lakatos, Alexandra I. T.
McConnell, Alicia M.
Wang, Poguang
Mueller, Alina
Kawakami, Akinori
Tsoi, Jennifer
Szabolcs, Botond L.
Ascsillán, Anna A.
Suita, Yusuke
Igras, Vivien
Lo, Jennifer A.
Hsiao, Jennifer J.
Lapides, Rebecca
Pál, Dorottya M. P.
Lengyel, Anna S.
Navarini, Alexander
Okazaki, Arimichi
Iliopoulos, Othon
Németh, István
Graeber, Thomas G.
Zon, Leonard
Giese, Roger W.
Kemeny, Lajos V.
Fisher, David E.
Funding for this research was provided by:
Mildred Scheel Grant of the German Cancer Society and the Filling the Gap grant of the University of Zurich, Switzerland
Filling the Gap grant of the University of Zurich
NIH (P01 CA244118, R01 AR072304)
Melanoma Research Alliance (691165)
János Bolyai Research Scholarship of the Hungarian Academy of Sciences
Development and Innovation Office (OTKA FK138696)
KIM NKFIA (TKP-2021-EGA-05)
KIM (NKFIA 2022-2.1.1-NL-2022-00005)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Article History
Received: 26 March 2024
Accepted: 3 September 2024
First Online: 14 September 2024
Competing interests
: Dr. Fisher has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. Dr. Fisher’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. Dr. Roider is a shareholder and founder of Maximon AG and its holding ventures. All other authors declare no conflicts of interest. All other authors declare they have no competing interests.